Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.
Gil Roth
Advertisement
Gil Roth is president of the Pharma & Biopharma OutsourcingAssociation, gil.roth@pharma-bio.org.
Articles by Gil Roth
The outlook for the CMO and CDMO industry may be affected by ever-changing politics.
Advertisement
Latest Updated Articles
- Viewpoint: Challenges and Opportunities for CDMOs
February 1st 2017
- CDMOs: New Administration, New Frontier
August 1st 2017
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
5